Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.
When Villanova hosted the first women’s Big 5 Classic tripleheader last year, the Wildcats intended to cap it off by winning the title. Instead, the Temple Owls spoiled the party plans and left the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback